Immunocytochemistry was performed as published.
24 Cell-specific markers were anti-glial fibrillary acidic protein (Z0334, 1:500; Dako Corp., Carpinteria, CA); anti-γ aminobutyric acid (1:2000; Protos Biotech Corp., New York, NY); anti-glycine (1:100; Robert Marc, University of Utah, Salt Lake City); anti-calbindin-D (C8666, 1:250; Sigma-Aldrich Corp., St. Louis, MO); anti-cellular retinaldehyde binding protein (1:500; John Saari, University of Washington, Seattle); PNA-rhodamine (RL1072, 1:100; Vector Laboratories, Inc.); anti-BrdU (G3G4, 1:50; Developmental Studies Hybridoma Bank, Iowa City, IA); anti-L7 (1:250, James Morgan, St. Jude’s Children Research Hospital, Memphis, TN); mouse anti-rod opsin (4D2, 1:80; Robert Molday, University of British Columbia, Vancouver, Canada); sheep anti-rod opsin (1:1000; David Papermaster, University of Connecticut, Farmington, CT); anti-arrestin (A9C6, 1:1000; Larry Donoso, Wills Eye Institute, Philadelphia, PA); anti-recoverin (P26, 1:1000; Alexander Dizhoor, Kresge Eye Institute, Detroit, MI); anti-blue cone opsin (JH455, 1:5000; Jeremy Nathans, Johns Hopkins University, Baltimore, MD); anti-peripherin-2 (Per-5H2, 1:30; Robert Molday); anti-ROM-1 (1:20; Roderick McInnes, University of Toronto, Ontario, Canada), and anti-RP1 (1:1000; Qin Liu, Scheie Eye Institute, Philadelphia, PA). Control sections were treated identically but with omission of primary antibody. Secondary antibodies (donkey anti-rabbit, anti-mouse, anti-guinea pig, anti-chicken) were labeled with Cy-2 (green) or Cy-3 (red; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). Nuclei were counterstained with DAPI (μg/mL)–supplemented mounting medium (Vectashield; Vector Laboratories, Inc.). Sections were analyzed by fluorescence microscopy, and digitized images were acquired as described earlier.